The Bottom Line
Women’s heart health is a cost, utilization, and quality gap hiding inside most health plan strategies. Cardiovascular risk in women is often silent and missed during key life-stage transitions, creating downstream exposure in avoidable events, medication-taking gaps, and CBP performance.
- Plan Priority Gap: 95% say heart health is important, but only 29% are prioritizing it
- Awareness Gap: Only 61% identify heart disease as the leading cause of death for women
- Financial Impact: Poor medication adherence is associated with $3,900 per person per year in avoidable costs
- Clinical Opportunity: High-risk women using Hello Heart saw an average 18 mmHg systolic BP reduction after about 1 year
A cost, utilization, and quality gap hiding in plain sight
Most women's health strategies are built around reproductive care. That's not wrong, but it is incomplete. And for health plans, the gap between those two things is showing up in avoidable costs.
Plan leaders already know heart disease drives cost. Our 2026 survey found 95% of plan leaders say addressing heart health is important, but only 29% are prioritizing it in a way that changes outcomes. And only 61% correctly identify heart disease as the leading cause of death for women.
That awareness gap matters because cardiovascular risk in women is often silent, missed, and only addressed after it has become a high-cost event. It’s a risk identification and strategy gap—and it shows up directly in cost, utilization, and blood pressure performance.
You can't manage what is silent
We run a sick care system, not a health care system. We wait for the event—the heart attack, the stroke, the hospitalization—and then we respond.
But high cholesterol and blood pressure are silent. Cardiovascular risk can creep up while your members feel perfectly fine. When it is missed in women, it shows up later as uncontrolled blood pressure, medication-taking gaps, avoidable emergency department visits, and higher-acuity hospitalizations.
Heart disease is already one of the most significant drivers of total cost of care. When risk is identified late, plans are no longer managing prevention. They’re managing consequences.
Poor medication adherence alone is associated with $3,900 per person per year in avoidable costs and preventable hospitalizations.
Different lens, same patient
One of the most persistent failures in how we approach women's health is fragmentation. The OB-GYN looks through one lens, the primary care physician looks through another, and the cardiologist enters the picture much later, often after the event.
From a plan perspective, that fragmentation translates into delayed recognition of risk that was visible much earlier.
Women's health programs are still often designed around maternity, reproductive care, and cancer screening. Meanwhile, the condition that drives the greatest long-term mortality and cost—cardiovascular disease—rarely shows up in that strategy.
And the consequences are not theoretical. Women are twice as likely to die from complications of a heart attack compared to men, which is a sign of delayed recognition, delayed escalation, and higher downstream cost.
Postpartum care is a particularly stark example. Cardiovascular conditions are the leading cause of maternal death in the United States, and 1 in 4 of those deaths involves cardiovascular or hypertensive conditions. Yet most women receive a single postpartum follow-up visit.
When cardiologists and OB-GYNs aren't coordinating, rising blood pressure goes undetected—and what could have been managed with medication becomes a preventable emergency.
Risk appears in patterns
Women's cardiovascular risk doesn’t suddenly emerge one day. It builds in a predictable pattern, but the system isn’t designed to catch it when it’s most visible.
Plans often rely on annual screenings, episodic office visits, and broad outreach. Those approaches miss what happens in between.
The most important signals show up during specific life-stage transitions: a new hypertension diagnosis, pregnancy and postpartum changes, and the menopausal transition.
For plan leaders, the diagnostic questions are different than the clinical ones:
- Are we identifying risk early enough to change utilization?
- Are we treating blood pressure control as part of women's health, or only as a chronic condition metric?
- Are we relying on visits and screenings to detect risk that is building silently between them?
- Are we measuring this problem in terms of total cost of care, avoidable utilization, and quality performance?
Let me be specific about menopause, because the clinical reality is more serious than most plans recognize.
Prior to perimenopause, women have roughly half the cardiovascular risk of men. When estrogen drops, that protection disappears. Arterial stiffness increases, sympathetic tone rises, and nitric oxide decreases. Blood pressure doesn't just rise, it accelerates along a steeper trajectory than it does in men.
The consequence is measurable: Stage 2 hypertension is associated with a 250% higher risk of heart attack in women compared to men. And the early warning signs—vasomotor symptoms like hot flashes—are early indicators of advancing heart disease.
When plans categorize menopause under reproductive health and leave it there, they miss a window when cardiovascular risk is visible and still modifiable. Miss it, and that reversible risk hardens into structural disease—the kind that shows up as an expensive hypertensive crisis, stroke, or heart failure admission.
The opportunity is earlier, not louder
High-cost cardiovascular events don't happen suddenly. Rising systolic blood pressure, metabolic changes, and missed medication doses typically evolve 12 to 36 months in advance of an acute event.
The greatest clinical and economic leverage exists in that upstream window, not after the hospitalization.
The problem is that most plans rely on the annual visit to surface that risk, and this is structurally insufficient for the job.
A physician, pressed for time, may brush off an elevated reading as white-coat syndrome or stress. The patient leaves without escalation, and months pass with rising blood pressure and missed doses entirely outside clinical visibility.
Within 6 to 12 months of that missed window, reversible risk can begin to harden into structural disease—vascular remodeling, plaque instability, early heart failure changes.
By the next annual visit, the opportunity for true prevention has closed. The plan is now paying for complex coronary disease, emergency care, or inpatient stays rather than inexpensive preventive management.
Plans that move earlier, before risk becomes a crisis, are the ones that will see tighter blood pressure control, fewer avoidable admissions, stronger quality performance, and more defensible ROI.
Where this becomes a plan-level decision
The opportunity for plans is to recognize where women's cardiovascular risk becomes measurable and intervene before it becomes cost.
Hello Heart's published outcomes for female users show what that looks like in practice:
- Among high-risk women with baseline systolic BP above 140, the average reduction was 18 mmHg—associated with a 30% decrease in coronary heart disease risk and 47% decrease in stroke risk
- 2 in 3 women lowered or maintained blood pressure below 130/80 after approximately one year on Hello Heart
- 85% of female users who had 5 or more irregular heartbeats detected accessed their clinician report—a pathway to escalate care before a catastrophic event, not after
The decisions you make today about how you identify and manage risk will determine the cost profile of your population tomorrow.
A final thought
The blind spots are predictable, the risk is measurable, and the cost of waiting is real.
Women's heart health needs to be integrated into how plans think about cost, quality, and risk. Because ultimately, no women's health strategy is complete without protecting women's hearts.
Read our guide for health plans to learn the specific moments when women's cardiovascular risk is most often missed. You’ll also see what it looks like to build an operational response before it becomes cost.
